3-Fluoro-5-((7-(methylsulfonyl)-3-oxo-2,3-dihydrospiro[indene-1,2'-[1,3]dioxolan]-4-YL)oxy)benzonitrile
[CAS# 1672668-41-5]

Identification

• Classification: Organic raw materials >> Organic fluorine compound >> Fluorobenzonitrile series
• Name: 3-Fluoro-5-((7-(methylsulfonyl)-3-oxo-2,3-dihydrospiro[indene-1,2'-[1,3]dioxolan]-4-YL)oxy)benzonitrile
• Molecular Formula: C₁₉H₁₄FNO₆S
• Molecular Weight: 403.38
• CAS Registry Number: 1672668-41-5
• SMILES: CS(=O)(=O)C1=C2C(=C(C=C1)OC3=CC(=CC(=C3)C#N)F)C(=O)CC24OCCO4

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H315-H319-H335
• Safety Statements: P261-P305+P351+P351-P302+P352

Discovery and Applications

3-Fluoro-5-((7-(methylsulfonyl)-3-oxo-2,3-dihydrospiro[indene-1,2'-[1,3]dioxolan]-4-yl)oxy)benzonitrile is a complex organic compound that has gained attention for its potential applications in medicinal chemistry and materials science. Its discovery is linked to ongoing research into novel inhibitors targeting key enzymes in disease pathways, particularly in the treatment of cancer and inflammatory conditions. The structural features of this compound, including the spirocyclic indene-dioxolane core and the methylsulfonyl group, contribute to its high specificity and activity.

The synthesis of this compound typically involves multi-step organic transformations, starting with the preparation of the indene intermediate, followed by functionalization to introduce the dioxolane ring. Fluorination and benzonitrile substitution are key steps in refining the molecule’s biological properties and enhancing its stability. This route often requires careful control of reaction conditions to ensure high yield and purity.

Applications of 3-Fluoro-5-((7-(methylsulfonyl)-3-oxo-2,3-dihydrospiro[indene-1,2'-[1,3]dioxolan]-4-yl)oxy)benzonitrile have been explored in the development of new pharmaceuticals, where its inhibitory effects on specific enzymes demonstrate potential in preclinical models. Its incorporation into targeted therapies may offer improved outcomes for patients with drug-resistant cancers or chronic diseases.

Further research into the compound’s mechanism of action and optimization of its pharmacokinetic profile continues to expand its relevance in drug development pipelines. Ongoing studies are evaluating its compatibility with combination therapies to enhance efficacy and reduce side effects.

References

2022. Synthesis of Belzutifan. Synfacts.
DOI: 10.1055/s-0041-1738315